Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

Kostas Biliouris’s rating is based on several compelling factors that highlight Legend Biotech’s strong market position and future potential. The increasing uptake of Carvykti, driven by its ...

Legend Biotech Corporation (NASDAQ ... In the third quarter, we are pleased that CARVYKTI cells continued their strong ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

CARVYKTI demonstrated a 45% reduction in the risk of death compared to standard therapies in multiple myeloma patients.

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Legend Biotech (NASDAQ:LEGN) is scheduled to announce Q3 earnings results on Tuesday, November 12th, before market open. The consensus EPS Estimate is -$0.57 and the consensus Revenue Estimate is $146 ...

One target of the investigation was Legend Biotech, a former business unit of GenScript ... Legend has become a force partnering with Johnson & Johnson on CAR-T multiple myeloma therapy Carvykti.

Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the ...

Emergent BioSolutions appointed Dr. Simon Lowry as chief medical officer and head of research and development. CureVac named ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...